April 12, 2017
argenx enters Phase II trial of CTCL drug
argenx has initiated a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 12, 2017
FDA OKs Neurocrine Biosciences’s neurological disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences’s Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia.
April 11, 2017
Diplomat welcomes new CFO
Diplomat Pharmacy has appointed Atul Kavthekar as chief financial officer and treasurer, effective May 1, 2017.
April 11, 2017
BMS, Apexigen team up to test combination of their cancer drugs
Bristol-Myers Squibb and Apexigen, a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, have started a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors.
April 11, 2017
Roche’s Alecensa beats crizotinib in certain lung cancer
Roche’s randomised phase III ALEX study showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
April 11, 2017
Nicox announces PDUFA date for Zerviate NDA
U.S. Food and Drug Administration (FDA) has set a PDUFA date of September 8, 2017 for its decision on the New Drug Application (NDA) for Nicox’s Zerviate (cetirizine ophthalmic solution) 0.24%.
April 11, 2017
Short: Akers Biosciences reports $3.3M net loss
Akers Biosciences, a developer of rapid health information technologies, has reported its financial results for the fiscal year ended December 31, 2016.
April 11, 2017
J&J’s subsidiary Codman Neuro buys Irish’s Neuravi Limited
Johnson & Johnson’s company Codman Neuro has acquired Neuravi Limited, a company dedicated to advancing neurovascular therapies and improving clinical outcomes for acute ischemic stroke patients.
April 10, 2017
Twenty-one countries vie to host EU drug agency after Brexit
The European Medicines Agency has had expressions of interest to host the London-based regulator from 21 of the 27 countries that will form the European Union once Britain leaves, revealing rivalry from Amsterdam to Zagreb for a prized institution.
April 10, 2017
Akers Biosciences to market Heparin PF4 rapid test in Puerto Rico
Akers Biosciences, a developer of rapid health information technologies, has begun marketing its rapid test for heparin-induced thrombocytopenia (“HIT”) to the large number of hospital facilities in Puerto Rico as an extension of the company’s strategy to accelerate U.S. sales of its flagship product.